DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rhinitis, Allergic, Perennial

Intervention: Mometasone furoate (Drug); Placebo (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Merck Sharp & Dohme Corp.

Summary

This is a multicenter, randomized, parallel design, double-blind study of mometasone furoate (MF) in pediatric subjects with perennial allergic rhinitis. The subjects 5 to 15 years of age with perennial allergic rhinitis will enter a no-treatment observation period of 7 days at minimum and eligibility for inclusion in this study will be assessed. Following the observation period, eligible subjects will be randomized to MF or MF placebo for a 2-week double-blind treatment. At each clinic visit (at the start of treatment and after 1 and 2 weeks of treatment or at discontinuation), nasal symptom scores, nasal findings, and adverse events (AEs), will be evaluated. A 30-day follow-up visit will take place after the completion (or discontinuation) of the 2-week treatment period, to confirm presence or absence of serious adverse events (SAEs) and trial procedure-related AEs.

Clinical Details

Official title: Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Protocol No.P06332)

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Change From Baseline in the Total Nasal Symptom Score at 2 Weeks

Secondary outcome: Change From Baseline in the Total Nasal Symptom Score at 1 Week

Eligibility

Minimum age: 5 Years. Maximum age: 15 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Pediatric subjects with perennial allergic rhinitis who satisfy all of the following

main criteria:

- Subjects having symptoms of perennial allergic rhinitis of moderate to severe

degree, after the pretreatment observation period.

- Subjects confirmed to be allergic to non-seasonal environmental antigens (e. g.,

house dust-mite antigen).

- Male or female outpatients aged 5 to 15 years at the time of providing informed

consent. Exclusion Criteria:

- Subjects for whom any of the main exclusion criteria below is applicable will not be

registered in this study.

- Subjects with coexisting tuberculous disease or lower respiratory tract

infection and subjects who have a nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.) requiring treatment at the time of registration

- Subjects with coexisting infections or systemic mycosis for which there are no

effective antibiotics

- Subjects with repeated epistaxis

- Subjects who have nasal septum ulcers, nasal surgery, or nasal trauma, which

have not healed

- Subjects with severe hepatic, renal, cardiac, hematological disease, diabetes

mellitus, hypertension, or other serious coexisting diseases and whose general condition is poor

- Subjects with complication of vasomotor rhinitis or eosinophilic rhinitis.

- Subjects with nasal conditions (infectious sinusitis, hypertrophic rhinitis,

acute or chronic rhinitis, nasal polyps, septal deviation, etc.) which may interfere with the evaluation of the efficacy of the study drug.

Locations and Contacts

Additional Information

Starting date: June 2010
Last updated: March 30, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017